+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Semi-synthetic ß-lactam Antibiotics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Semi-synthetic ß-lactam Antibiotics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Semi-synthetic ß-lactam Antibiotics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6079775
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The semi-synthetic β-lactam antibiotics sector stands at the crossroads of innovation and global health imperatives. As resistance patterns evolve and regulatory landscapes shift, stakeholders must navigate a complex matrix of scientific breakthroughs, supply chain dynamics, and policy reforms. This executive summary introduces the foundational concepts underpinning carbapenems, cephalosporins, monobactams, and penicillins-each engineered to disrupt bacterial cell wall synthesis through the characteristic β-lactam ring. By enhancing natural molecular frameworks with synthetic modifications, developers have achieved broader spectra of activity, improved pharmacokinetics, and reduced toxicity profiles. Moreover, this introduction frames the urgency of optimizing these agents amid rising antimicrobial resistance, supply constraints, and tariff-induced cost pressures. Throughout this summary, readers will gain clarity on the major forces shaping market behavior, segmentation strategies that pinpoint growth vectors, regional nuances influencing adoption, and competitive tactics driving R&D and commercialization. By setting this stage, decision-makers can align their portfolios, operational models, and strategic roadmaps to harness opportunities while mitigating emerging risks in this vital therapeutic category.

Transformative Shifts Reshaping the β-Lactam Antibiotics Landscape

Over the past decade, the β-lactam antibiotics landscape has undergone transformative shifts driven by scientific innovation, regulatory realignment, and shifting market demands. First, advances in medicinal chemistry have yielded next-generation cephalosporins with enhanced stability against extended-spectrum β-lactamases, while novel carbapenem analogues address multi-drug resistant pathogens. Concurrently, precision dosing guided by pharmacogenomics is reshaping therapeutic regimens, improving efficacy and safety. In parallel, regulatory agencies are accelerating pathways for agents targeting critical priority pathogens, encouraging public-private partnerships and adaptive trial designs to fast-track approvals. From a commercial perspective, digital manufacturing platforms and continuous flow synthesis are lowering production costs, increasing flexibility, and reducing environmental impact. Moreover, antibiotic stewardship programs now integrate real-time diagnostic tools, enabling targeted therapy and curbing resistance emergence. These concurrent developments-from R&D breakthroughs to manufacturing innovations and policy reforms-have collectively redefined competitive dynamics and heightened the imperative for agile strategies. As a result, industry participants must continually adapt to ensure their product pipelines, supply chains, and market access models align with this rapidly evolving terrain.

Analyzing the Cumulative Impact of 2025 U.S. Tariffs on β-Lactams

In 2025, newly imposed U.S. tariffs on critical raw materials and active pharmaceutical ingredients have created ripple effects across the semi-synthetic β-lactam supply chain. Key precursors imported from Europe and Asia have seen incremental cost increases, prompting manufacturers to reassess contract terms and regional sourcing strategies. As a result, production costs for Ertapenem, Cefuroxime, and Aztreonam have risen, putting margin pressure on both originator firms and generic producers. Consequently, procurement teams are diversifying suppliers, negotiating volume-based discounts, and exploring backward integration to secure feedstock at stable prices. Additionally, these tariffs have accelerated collaborations with domestic API manufacturers, driving investments in local capacity expansion and technology transfer agreements. From a pricing perspective, wholesalers and hospital pharmacies are adjusting their reimbursement models, factoring in the elevated landed costs. At the same time, stakeholder dialogues between industry associations and regulatory bodies are intensifying, seeking tariff relief or targeted exemptions for essential medicines. Taken together, the cumulative tariff impact underscores the critical need for proactive supply chain resilience, cost management, and policy advocacy to sustain patient access and commercial viability.

Key Segmentation Insights Across Product, Administration, and Applications

Market segmentation reveals distinct performance patterns and untapped opportunities across product categories, modes of administration, end users, distribution channels, patient demographics, therapeutic applications, formulations, duration of action, and dosage concentrations. On the product front, the Carbapenem Group-encompassing Ertapenem, Imipenem, and Meropenem-continues to dominate due to its efficacy against multi-drug resistant strains, while the Cephalosporin Group’s Cefadroxil, Cefalexin, and Cefuroxime maintain strong demand in outpatient settings. Monobactam’s Aztreonam fills a niche in penicillin-allergic populations, and the Penicillin Group’s Amoxicillin, Ampicillin, and Nafcillin remain staples in broad-spectrum therapy. Regarding administration routes, injectable solutions command immediate utilization in hospital critical care units, oral tablets capture primary care volumes, and topical creams serve dermatology and minor skin infection segments. Within end-user categories, clinics-spanning both group practices and independent clinics-drive early-stage prescribing, homecare settings support long-term outpatient regimens, and hospitals-both public and private-lead in high-intensity treatments. Distribution pathways through hospital pharmacies ensure formulary inclusion, online pharmacies offer convenient access for chronic use, and retail pharmacies remain pivotal for over-the-counter penicillin derivatives. Age group analysis highlights adult and geriatric cohorts as primary consumers, whereas pediatric demand, split between childcare and neonatal applications, underscores the need for weight-based dosing solutions. Therapeutically, β-lactams address gastrointestinal, respiratory, skin, and urinary tract infections, with varying spectrum and potency requirements. Formulations in capsules, powder, and suspensions cater to patient preference and stability needs, while intermediate-acting, long-acting, and short-acting profiles allow dosing flexibility. Finally, high-dose, medium-dose, and low-dose options ensure tailored regimens aligned with infection severity and resistance concerns. Together, these segmentation insights offer a granular roadmap for prioritizing R&D investments, channel strategies, and targeted marketing efforts.

Regional Dynamics Influencing the Semi-Synthetic β-Lactam Market

Regional dynamics play a pivotal role in shaping market trajectories and competitive positioning across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, established manufacturing infrastructure, strong generic penetration, and comprehensive reimbursement frameworks support wide β-lactam adoption, while collaborative initiatives between public health agencies and industry stakeholders drive stewardship and surveillance efforts. Meanwhile, Europe Middle East & Africa benefit from regulatory harmonization through agencies such as EMA, promoting cross-border market entry and joint procurement models, although varied national healthcare budgets and antibiotic stewardship policies introduce complexity. In the Asia-Pacific region, rapid urbanization, rising prevalence of infectious diseases, and government incentives for local pharmaceutical production have catalyzed demand growth. At the same time, price-sensitive markets in South and Southeast Asia prioritize cost-effective formulations, prompting multinational and local players to optimize cost structures. Across all regions, digital health platforms are gaining traction to enhance supply chain visibility, patient adherence, and real-world evidence collection, underscoring the global convergence toward integrated, data-driven approaches in antibiotic management.

Strategic Profiles of Leading Players Shaping Market Progression

Leading pharmaceutical companies are actively reshaping the semi-synthetic β-lactam landscape through strategic investments, partnerships, and innovation pipelines. AbbVie Inc. and Allergan Inc. leverage robust R&D platforms to enhance molecule stability and spectrum of activity. Astellas Pharma Inc. and Bayer AG focus on continuous manufacturing technologies to drive cost efficiencies and scale. Bristol-Myers Squibb Company and F. Hoffmann-La Roche AG prioritize antibiotic stewardship collaborations and novel clinical trial designs targeting resistant pathogens. Cipla Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Mylan N.V., and Sun Pharmaceutical Industries Ltd. capitalize on generic portfolios and regional manufacturing hubs to deliver affordable high-quality APIs. Gilead Sciences Inc. and GSK PLC integrate advanced diagnostics with therapeutic regimens to enable precision dosing and optimize patient outcomes. Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Zydus Cadila Healthcare Limited deploy global distribution networks and hybrid commercialization models to expand market reach. Many of these players are forging cross-sector alliances, licensing proprietary β-lactam precursors, and co-investing in emerging markets to bolster capacity. Collectively, their strategic moves-from targeted M&A to platform modernization-underscore the collaborative impetus driving new antibiotic solutions while navigating regulatory and pricing headwinds.

Actionable Recommendations for Industry Leaders Navigating Change

To thrive in this evolving ecosystem, industry leaders should prioritize diversification of supply chains by establishing dual-sourcing arrangements and investing in localized API facilities. They must accelerate development of next-generation formulations that combine long-acting profiles with superior β-lactamase stability. Engaging in strategic alliances with diagnostic and digital health providers can unlock precision prescribing and support real-time resistance monitoring. Companies should also advocate for adaptive regulatory pathways, demonstrating value through real-world evidence and cost-effectiveness analyses. Intensifying antibiotic stewardship collaborations with hospitals, clinics, and homecare networks will strengthen appropriate use and prolong therapeutic lifespans. Finally, embedding sustainability in manufacturing-via continuous flow chemistry and green solvents-will mitigate environmental impact and align with global ESG priorities. By implementing these recommendations, stakeholders can secure competitive advantage while safeguarding patient access and public health outcomes.

Conclusion: Steering a Resilient and Sustainable Market Future

In summary, the semi-synthetic β-lactam antibiotics arena is characterized by rapid scientific progress, evolving regulatory frameworks, and intensified supply chain scrutiny. The sector’s resilience hinges on understanding the nuanced segmentation across products, administration routes, end-user profiles, and therapeutic indications. Regional insights reveal distinct market imperatives within the Americas, Europe Middle East & Africa, and Asia-Pacific, while strategic profiles of leading firms illuminate best practices in innovation, cost management, and market expansion. As companies confront tariff pressures and resistance challenges, proactive strategies-ranging from diversified sourcing and advanced manufacturing to digital integrations and stewardship partnerships-will define market leadership. By aligning R&D investments, operational excellence, and stakeholder engagement, decision-makers can position their portfolios to capture emerging opportunities, mitigate risk, and ultimately improve patient outcomes in the fight against bacterial infections.

Market Segmentation & Coverage

This research report categorizes the Semi-synthetic β-lactam Antibiotics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Carbapenem Group
    • Ertapenem
    • Imipenem
    • Meropenem
  • Cephalosporin Group
    • Cefadroxil
    • Cefalexin
    • Cefuroxime
  • Monobactam Group
    • Aztreonam
  • Penicillin Group
    • Amoxicillin
    • Ampicillin
    • Nafcillin
  • Injectable Solutions
  • Oral Tablets
  • Topical Creams
  • Clinics
    • Group Practices
    • Independent Clinics
  • Homecare Settings
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Adult
  • Geriatric
  • Pediatric
    • Child Care
    • Neonatal
  • Gastrointestinal Infections
  • Respiratory Tract Infections
  • Skin Infections
  • Urinary Tract Infections
  • Capsules
  • Powder
  • Suspensions
  • Intermediate-Acting
  • Long-Acting
  • Short-Acting
  • High-Dose
  • Low-Dose
  • Medium-Dose

This research report categorizes the Semi-synthetic β-lactam Antibiotics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Semi-synthetic β-lactam Antibiotics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Allergan Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • F.Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila Healthcare Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Semi-synthetic ß-lactam Antibiotics Market, by Product Type
8.1. Introduction
8.2. Carbapenem Group
8.2.1. Ertapenem
8.2.2. Imipenem
8.2.3. Meropenem
8.3. Cephalosporin Group
8.3.1. Cefadroxil
8.3.2. Cefalexin
8.3.3. Cefuroxime
8.4. Monobactam Group
8.4.1. Aztreonam
8.5. Penicillin Group
8.5.1. Amoxicillin
8.5.2. Ampicillin
8.5.3. Nafcillin
9. Semi-synthetic ß-lactam Antibiotics Market, by Mode of Administration
9.1. Introduction
9.2. Injectable Solutions
9.3. Oral Tablets
9.4. Topical Creams
10. Semi-synthetic ß-lactam Antibiotics Market, by End-User
10.1. Introduction
10.2. Clinics
10.2.1. Group Practices
10.2.2. Independent Clinics
10.3. Homecare Settings
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
11. Semi-synthetic ß-lactam Antibiotics Market, by Channel of Distribution
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Semi-synthetic ß-lactam Antibiotics Market, by Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
12.4.1. Child Care
12.4.2. Neonatal
13. Semi-synthetic ß-lactam Antibiotics Market, by Therapeutic Application
13.1. Introduction
13.2. Gastrointestinal Infections
13.3. Respiratory Tract Infections
13.4. Skin Infections
13.5. Urinary Tract Infections
14. Semi-synthetic ß-lactam Antibiotics Market, by Formulation
14.1. Introduction
14.2. Capsules
14.3. Powder
14.4. Suspensions
15. Semi-synthetic ß-lactam Antibiotics Market, by Duration of Action
15.1. Introduction
15.2. Intermediate-Acting
15.3. Long-Acting
15.4. Short-Acting
16. Semi-synthetic ß-lactam Antibiotics Market, by Concentration
16.1. Introduction
16.2. High-Dose
16.3. Low-Dose
16.4. Medium-Dose
17. Americas Semi-synthetic ß-lactam Antibiotics Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Semi-synthetic ß-lactam Antibiotics Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Semi-synthetic ß-lactam Antibiotics Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. AbbVie Inc.
20.3.2. Allergan Inc.
20.3.3. Astellas Pharma Inc.
20.3.4. Bayer AG
20.3.5. Bristol-Myers Squibb Company
20.3.6. Cipla Limited
20.3.7. Dr. Reddy's Laboratories Ltd.
20.3.8. F.Hoffmann-La Roche AG
20.3.9. Gilead Sciences Inc.
20.3.10. GlaxoSmithKline PLC
20.3.11. Lupin Limited
20.3.12. Merck & Co., Inc.
20.3.13. Mylan N.V.
20.3.14. Novartis AG
20.3.15. Novo Nordisk A/S
20.3.16. Pfizer Inc.
20.3.17. Sanofi S.A.
20.3.18. Sun Pharmaceutical Industries Ltd.
20.3.19. Teva Pharmaceutical Industries Ltd.
20.3.20. Zydus Cadila Healthcare Limited
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET MULTI-CURRENCY
FIGURE 2. SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET MULTI-LANGUAGE
FIGURE 3. SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2024 VS 2030 (%)
FIGURE 22. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2024 VS 2030 (%)
FIGURE 24. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY ERTAPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY IMIPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEFADROXIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEFALEXIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEFUROXIME, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AZTREONAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AMPICILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY NAFCILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY TOPICAL CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY GROUP PRACTICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHILD CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY NEONATAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY INTERMEDIATE-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HIGH-DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY LOW-DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MEDIUM-DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 116. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 118. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 119. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 120. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 121. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 124. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 125. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 126. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 128. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 131. CANADA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 132. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 134. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 135. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 136. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 137. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 142. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 143. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 144. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 146. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. MEXICO SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 198. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 200. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 201. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 202. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 203. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 206. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 208. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 210. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 212. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 213. CHINA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 214. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 215. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 216. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 217. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 218. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 219. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 222. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 223. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 224. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 226. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 228. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 229. INDIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 246. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 248. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 249. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 250. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 251. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 256. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 258. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 260. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 261. JAPAN SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 273. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 274. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 278. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM GROUP, 2018-2030 (USD MILLION)
TABLE 280. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN GROUP, 2018-2030 (USD MILLION)
TABLE 281. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MONOBACTAM GROUP, 2018-2030 (USD MILLION)
TABLE 282. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN GROUP, 2018-2030 (USD MILLION)
TABLE 283. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES SEMI-SYNTHETIC ?-LACTAM ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILL

Companies Mentioned

  • AbbVie Inc.
  • Allergan Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • F.Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila Healthcare Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Beta Lactam & Beta Lactamase Inhibitors Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Beta Lactam & Beta Lactamase Inhibitors Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Beta-Lactam and Beta-Lactamase Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Beta-Lactam and Beta-Lactamase Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Beta Lactam and Beta Lactamase Inhibitors - Global Strategic Business Report - Product Image

Beta Lactam and Beta Lactamase Inhibitors - Global Strategic Business Report

  • Report
  • 391 Pages
  • Global
From
Oral Antibiotics Market 2025-2033 - Product Image

Oral Antibiotics Market 2025-2033

  • Report
  • 147 Pages
  • Global
From
Beta-Lactamase Inhibitor - Pipeline Insight, 2025 - Product Image

Beta-Lactamase Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.